https://scholars.lib.ntu.edu.tw/handle/123456789/579808
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Huang S.-H. | en_US |
dc.contributor.author | Huang C.-H. | en_US |
dc.contributor.author | Wang N.-C. | en_US |
dc.contributor.author | Chen T.-C. | en_US |
dc.contributor.author | Lee Y.-T. | en_US |
dc.contributor.author | Lin S.-P. | en_US |
dc.contributor.author | Lin T.-Y. | en_US |
dc.contributor.author | Lin C.-Y. | en_US |
dc.contributor.author | Lee Y.-L. | en_US |
dc.contributor.author | Lee C.-H. | en_US |
dc.contributor.author | Chen C.-P. | en_US |
dc.contributor.author | KUAN-YIN LIN | en_US |
dc.contributor.author | Chen G.-J. | en_US |
dc.contributor.author | Liu C.-E. | en_US |
dc.contributor.author | Cheng S.-H. | en_US |
dc.contributor.author | Lu P.-L. | en_US |
dc.contributor.author | Yang C.-J. | en_US |
dc.contributor.author | CHIEN-CHING HUNG | en_US |
dc.contributor.author | on behalf of the Taiwan HIV Study Group | en_US |
dc.date.accessioned | 2021-08-27T06:48:50Z | - |
dc.date.available | 2021-08-27T06:48:50Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 0270-9139 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85067693124&doi=10.1002%2fhep.30495&partnerID=40&md5=50ccd254cb36aa76f181e1ca981d947c | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/579808 | - |
dc.description.abstract | Serological responses (Seroresponse) and durability of hepatitis A virus (HAV) vaccination are reduced among human immunodeficiency virus (HIV)-positive patients. Incidence of and associated factors with early seroreversion (loss of seroresponse) among HIV-positive patients who have achieved seroresponses after two doses of HAV vaccination remain unclear. In this multicenter study, we followed HIV-positive adults who had mounted seroresponses after completing two doses of HAV vaccination during a recent outbreak of acute hepatitis A between 2015 and 2017, a 1:4 case-control study was conducted to identify factors associated with seroreversion. Case patients were those with seroreversion, and controls were those with similar follow-up durations who were able to maintain seroresponses. During the study period, 49 of the 1,256 patients (3.9%) seroreverted after a median follow-up of 611 days. In a case-control study, seroreversion was more likely to occur in patients with a higher weight (adjusted odds ratio [aOR], 1.703; 95% confidence interval [CI], 1.292-2.323, per 10-kg increment) and HIV viremia at the time of vaccination (aOR, 2.922; 95% CI, 1.067-7.924), whereas positive seroresponse at 6 months of HAV vaccination and higher CD4 lymphocyte counts at vaccination were inversely associated with early seroreversion with an aOR of 0.059 (95% CI, 0.020-0.154) and 0.837 (95% CI, 0.704-0.979, per 100-cell/mm3increment), respectively, in multivariable analyses. Conclusion: During an outbreak setting, early seroreversion following two-dose HAV vaccination occurred in 3.9% of HIV-positive patients. Lower and delayed seroresponses to HAV vaccination, a higher weight, and HIV viremia and lower CD4 lymphocyte counts at the time of HAV vaccination were associated with early seroreversion. Regular monitoring of seroresponse and booster vaccination might be warranted, especially in HIV-positive adults with predictors of early seroreversion. ? 2019 The Authors. Hepatology published by Wiley Periodicals, Inc., on behalf of American Association for the Study of Liver Diseases. | - |
dc.publisher | John Wiley and Sons Inc | - |
dc.relation.ispartof | Hepatology | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | CD4 antigen; hepatitis A vaccine; immunoglobulin G; virus RNA; hepatitis A vaccine; acute hepatitis A; adult; antibody titer; Article; case control study; CD4 lymphocyte count; controlled study; epidemic; female; follow up; human; Human immunodeficiency virus infected patient; immune response; incidence; major clinical study; male; multicenter study (topic); nonhuman; priority journal; retrospective study; seroconversion; serology; seroreversion; vaccination; viremia; virus load; blood; clinical trial; hepatitis A; Human immunodeficiency virus infection; immunology; multicenter study; seroconversion; time factor; Adult; Case-Control Studies; Disease Outbreaks; Female; Hepatitis A; Hepatitis A Vaccines; HIV Seropositivity; Humans; Male; Retrospective Studies; Seroconversion; Time Factors | - |
dc.title | Early Seroreversion After 2 Doses of Hepatitis A Vaccination in Human Immunodeficiency Virus–Positive Patients: Incidence and Associated Factors | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1002/hep.30495 | - |
dc.identifier.pmid | 30614542 | - |
dc.identifier.scopus | 2-s2.0-85067693124 | - |
dc.relation.pages | 465-475 | - |
dc.relation.journalvolume | 70 | - |
dc.relation.journalissue | 2 | - |
item.openairetype | journal article | - |
item.fulltext | no fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.grantfulltext | none | - |
item.cerifentitytype | Publications | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Tropical Medicine and Parasitology | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.orcid | 0000-0001-6877-5345 | - |
crisitem.author.orcid | 0000-0001-7345-0836 | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。